ArticleNPJ breast cancer2024

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.

Stefania Morganti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.